Collaborative Arrangement, Expected Development Cost Funds, Year One

No definition available.

Name:	biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearOne
Namespace Prefix:	biib_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaborative Arrangement, Expected Development Cost Funds, Year Two

+ References

No definition available.

+ Details

Name:	biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearTwo
Namespace Prefix:	biib_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Estimated additional payments upon achievement of development and commercial milestones.

+ References

No definition available.

+ Details

Name:	biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones
Namespace Prefix:	biib_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Reduction Of Research And Development Expense

+ References

No definition available.

+ Details

Name:	biib_ReductionOfResearchAndDevelopmentExpense
Namespace Prefix:	biib_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=biib_MilestonePaymentFutureDevelopmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=biib_FelzartamabAndIzastobartHIB210Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=biib_MilestonePaymentOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=biib_MilestonePaymentTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=biib_MilestonePaymentCommercialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaborative and Other Relationships - Other Research and Discovery Arrangements and Funding Arrangements (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Feb. 11, 2025
Collaborative arrangements and non-collaborative arrangement transactions
Reduction of research and development expense	$ 50.0
Milestone Payment, Future Development
Collaborative arrangements and non-collaborative arrangement transactions
Estimated additional payments upon achievement of development and commercial milestones	250.0
Felzartamab And Izastobart/HIB210 \| Human Immunology Biosciences Pre-Existing In License Commitments \| Milestone Payment, One
Collaborative arrangements and non-collaborative arrangement transactions
Estimated additional payments upon achievement of development and commercial milestones	35.0
Felzartamab And Izastobart/HIB210 \| Human Immunology Biosciences Pre-Existing In License Commitments \| Milestone Payment, Two
Collaborative arrangements and non-collaborative arrangement transactions
Estimated additional payments upon achievement of development and commercial milestones	30.0
Felzartamab And Izastobart/HIB210 \| Human Immunology Biosciences Pre-Existing In License Commitments \| Milestone Payment, Future Development
Collaborative arrangements and non-collaborative arrangement transactions
Estimated additional payments upon achievement of development and commercial milestones	130.0
Felzartamab And Izastobart/HIB210 \| Human Immunology Biosciences Pre-Existing In License Commitments \| Milestone Payment, Commercial
Collaborative arrangements and non-collaborative arrangement transactions
Estimated additional payments upon achievement of development and commercial milestones	$ 640.0
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Collaborative arrangements and non-collaborative arrangement transactions
Expected receipts to co-fund development costs, current		$ 200.0
Expected receipts to co-fund development costs, noncurrent		$ 50.0